NMDA Receptor Antagonists

NMDA receptor antagonists play a crucial role in Alzheimer's disease and dementia by modulating glutamate activity in the brain. Glutamate, an excitatory neurotransmitter, is implicated in neurodegenerative processes when present in excess. NMDA receptor antagonists, such as memantine, work by blocking these receptors, thereby regulating glutamate levels and reducing neuronal damage associated with Alzheimer's disease progression. This class of drugs helps improve cognitive function and delay symptom progression by maintaining neurotransmitter balance. Unlike other treatments, NMDA receptor antagonists target specific mechanisms of neurodegeneration, offering a unique therapeutic approach in managing Alzheimer's disease and related dementias. Ongoing research continues to explore their efficacy and potential in providing symptomatic relief and possibly altering disease progression in affected individuals.

Committee Members
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Jacqueline Tuppen

Jacqueline Tuppen

Cogs Club, United Kingdom
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Yong Xiao Wang

Yong Xiao Wang

Albany Medical College, United States
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Kaoru Sakatani

Kaoru Sakatani

The University of Tokyo, Japan
Dementia 2023 Speakers
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Suren A Tatulian

Suren A Tatulian

University of Central Florida, United States
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Constantina Mizis

Constantina Mizis

The Latino Alzheimer’s and Memory Disorders Alliance, United States
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Paul Y Song

Paul Y Song

NKGen Biotech, United States
Speaker at Alzheimer’s Disease & Dementia Conference 2023 - Marco Ruggiero

Marco Ruggiero

Silver Spring Sagl, Switzerland
Tags
Facebook
Watsapp